These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35507498)

  • 1. Pembrolizumab in Early Triple-Negative Breast Cancer. Reply.
    Schmid P; Cortes J; Dent R
    N Engl J Med; 2022 May; 386(18):1771-1772. PubMed ID: 35507498
    [No Abstract]   [Full Text] [Related]  

  • 2. Pembrolizumab in Early Triple-Negative Breast Cancer.
    Ganguly S; Gogia A
    N Engl J Med; 2022 May; 386(18):1771. PubMed ID: 35507497
    [No Abstract]   [Full Text] [Related]  

  • 3. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
    Schmid P; Cortes J; Dent R; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Untch M; Fasching PA; Cardoso F; Andersen J; Patt D; Danso M; Ferreira M; Mouret-Reynier MA; Im SA; Ahn JH; Gion M; Baron-Hay S; Boileau JF; Ding Y; Tryfonidis K; Aktan G; Karantza V; O'Shaughnessy J;
    N Engl J Med; 2022 Feb; 386(6):556-567. PubMed ID: 35139274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
    Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
    Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab improves EFS in TNBC.
    Sidaway P
    Nat Rev Clin Oncol; 2022 Apr; 19(4):220. PubMed ID: 35217781
    [No Abstract]   [Full Text] [Related]  

  • 6. [New drug approval: Pembrolizumab - Neoadjuvant/adjuvant treatment for localized high-risk triple negative breast cancer].
    Minot-This MS; Deleuze A
    Bull Cancer; 2022 Oct; 109(10):988-989. PubMed ID: 35871860
    [No Abstract]   [Full Text] [Related]  

  • 7. Neoadjuvant chemoimmunotherapy in early triple-negative breast cancer: a new kid on the block?
    Rizzo A; Palmiotti G
    Immunotherapy; 2022 Jul; 14(10):755-758. PubMed ID: 35642433
    [No Abstract]   [Full Text] [Related]  

  • 8. Pembrolizumab for Early Triple-Negative Breast Cancer.
    Schmid P; Cortes J; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Foukakis T; Fasching PA; Cardoso F; Untch M; Jia L; Karantza V; Zhao J; Aktan G; Dent R; O'Shaughnessy J;
    N Engl J Med; 2020 Feb; 382(9):810-821. PubMed ID: 32101663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab plus chemotherapy in triple-negative breast cancer - Authors' reply.
    Cortes J; Rugo HS; Guo Z; Karantza V; Schmid P
    Lancet; 2021 Jul; 398(10294):24-25. PubMed ID: 34217393
    [No Abstract]   [Full Text] [Related]  

  • 10. Letter to the Editor Regarding "Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single Agent Pembrolizumab for High-Risk Early-Stage Triple Negative Breast Cancer in the United States".
    Sorscher S
    Adv Ther; 2023 Sep; 40(9):4111-4113. PubMed ID: 37432550
    [No Abstract]   [Full Text] [Related]  

  • 11. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
    Winer EP; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Zhou X; Karantza V; Mejia J; Cortes J;
    Lancet Oncol; 2021 Apr; 22(4):499-511. PubMed ID: 33676601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer.
    Shah M; Osgood CL; Amatya AK; Fiero MH; Pierce WF; Nair A; Herz J; Robertson KJ; Mixter BD; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L
    Clin Cancer Res; 2022 Dec; 28(24):5249-5253. PubMed ID: 35925043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pembrolizumab as neoadjuvant treatment of early triple-negative breast cancer].
    Dierks F; Pietsch E; Dunst J
    Strahlenther Onkol; 2020 Sep; 196(9):841-843. PubMed ID: 32561940
    [No Abstract]   [Full Text] [Related]  

  • 14. Bevacizumab in neoadjuvant chemotherapy increases the pathological complete response rate in patients with triple-negative breast cancer.
    Barton MK
    CA Cancer J Clin; 2014; 64(3):155-6. PubMed ID: 24639119
    [No Abstract]   [Full Text] [Related]  

  • 15. Pembrolizumab in Triple-Negative Breast Cancer. Reply.
    Cortes J; Zhou X; Schmid P
    N Engl J Med; 2022 Oct; 387(15):1436. PubMed ID: 36239658
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
    Nanda R; Liu MC; Yau C; Shatsky R; Pusztai L; Wallace A; Chien AJ; Forero-Torres A; Ellis E; Han H; Clark A; Albain K; Boughey JC; Jaskowiak NT; Elias A; Isaacs C; Kemmer K; Helsten T; Majure M; Stringer-Reasor E; Parker C; Lee MC; Haddad T; Cohen RN; Asare S; Wilson A; Hirst GL; Singhrao R; Steeg K; Asare A; Matthews JB; Berry S; Sanil A; Schwab R; Symmans WF; van 't Veer L; Yee D; DeMichele A; Hylton NM; Melisko M; Perlmutter J; Rugo HS; Berry DA; Esserman LJ
    JAMA Oncol; 2020 May; 6(5):676-684. PubMed ID: 32053137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.
    Schmid P; Salgado R; Park YH; Muñoz-Couselo E; Kim SB; Sohn J; Im SA; Foukakis T; Kuemmel S; Dent R; Yin L; Wang A; Tryfonidis K; Karantza V; Cortés J; Loi S
    Ann Oncol; 2020 May; 31(5):569-581. PubMed ID: 32278621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab plus chemotherapy in triple-negative breast cancer.
    Masuda J; Ozaki Y; Hara F; Kitano S; Takano T
    Lancet; 2021 Jul; 398(10294):24. PubMed ID: 34217392
    [No Abstract]   [Full Text] [Related]  

  • 19. Improved response rates shown with neoadjuvant and adjuvant pembrolizumab for triple-negative breast cancer with lymph node involvement.
    Printz C
    Cancer; 2020 Jan; 126(9):1827. PubMed ID: 32286699
    [No Abstract]   [Full Text] [Related]  

  • 20. Histologic subtypes in chemotherapy vs. sacituzumab sovitecan groups might affect progression-free and overall survival in metastatic triple-negative breast cancer.
    Altundag K
    J BUON; 2021; 26(3):1174-1175. PubMed ID: 34268994
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.